Anti-MPXV A35R (Clone MPXV-56) – Purified No Carrier Protein

MPXV-56 was generated from peripheral blood mononuclear cells obtained from donors who had either recovered from naturally-occurring MPXV infection or been immunized against vaccinia⁵.

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Standard Overnight on Blue Ice.

ELISA
N

Anti-MPXV A35R (clone name: MPXV-56) is reactive against the EV membrane protein encoded by ORF A35R of monkeypox virus (Homologous to Vaccinia virus A33R).

Complementary screening approaches were used to identify orthopoxvirus-specific mAbs to MPXV, cowpox virus (CPXV), variola virus (VARV), and vaccinia virus (VACV). MPXV-56 is reactive against VACV antigen and lysate, CPXV lysate, MPXV lysate, and VARV antigen and lysate. MPXV-56 binds to VACV and VARV purified antigen and weakly binds virus-infected cell lysates of VACV, CPXV, and MPXV. MPXV-56 neutralizes VACV EV plus complement (+C’) but not MV, MV+C’, or EV.

MPXV-56 also neutralizes CPXV EV+C’ and MV+C' but not EV.

Monkeypox virus (MPXV) is a zoonotic member of the Orthopoxvirus genus in the Poxviridae family¹. It is the next most pathogenic poxvirus after smallpox. Two genetic clades, West African and Central African (Congo Basin), have been characterized; the latter is capable of human-to-human transmission^1,2. Monkeypox has gained clinical relevance due to the eradication of smallpox, which has created opportunities for increased prevalence and viral mutations that may affect virulence^{1, 2}. Rodents are thought to be the natural reservoir, with transmission through contact with bodily fluids and feces. Case fatality rates are <1% and up to 11% for the West African and Central Basin clades, respectively^1,2. An infection with one orthopoxvirus of any one species, or vaccinia virus vaccination, protects against infection by other orthopoxviruses^3,4,5.

MPXV is an enveloped virus with a linear, double-stranded DNA genome² and a large, complex proteome of over 200 proteins⁶. During infection, the virus exists in two antigenically distinct forms: mature virions (MV) or enveloped virions (EV)⁶.

A33 is a surface antigen on the enveloped virion.

1. Sklenovská N, Van Ranst M. Front Public Health. 6:241. 2018.
2. Moore M, Zahra F. 2021 Oct 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.
3. McConnell S, Herman YF, Mattson DE, et al. Am J Vet Res. 25:192-195. 1964.
4. Hammarlund E, Lewis MW, Carter SV, et al. Nat Med. 11(9):1005-1011. 2005.
5. Gilchuk I, Gilchuk P, Sapparapu G, et al. Cell. 167(3):684-694.e9. 2016.
6. Moss B. Immunol Rev.239:8–26. 2011.